In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $72.31, marking a -2.24% move from the previous day.

On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...

One of the most revolutionary tools in cutting-edge medicine is a molecular scalpel so precise that it can modify defective ...

Precision genome editing is revolutionizing the treatment of rare genetic disorders, offering hope through customized therapies while raising ethical and medical concerns.

CRISPR Therapeutics’ stock is surging as in-vivo therapies show promise. Learn about CRSP stock's risks, long-term upside, ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

CRISPR Therapeutics (CRSP) has filed a prospectus supplement with the U.S. SEC to sell up to $600 million worth of its common ...

CRISPR-based tools can’t easily access the DNA in these organelles, but researchers are finding other ways in.

In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...

Fintel reports that on October 17, 2025, B of A Securities maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class ...